MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

187.13 +3.29 (+1.79%)
Streaming Delayed Price Updated: 12:28 PM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 306,534
Open 186.16
Bid (Size) 187.11 (100)
Ask (Size) 187.54 (100)
Prev. Close 183.84
Today's Range 185.54 - 190.09
52wk Range 110.03 - 202.41
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
From Biogen Inc.
Via GlobeNewswire

Performance

YTD
+5.2%
+5.2%
1 Month
-2.4%
-2.4%
3 Month
+5.8%
+5.8%
6 Month
+35.1%
+35.1%
1 Year
+36.8%
+36.8%

More News

Read More
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi ↗
Via Stocktwits
News headline image
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
From Biogen Inc.
Via GlobeNewswire
News headline image
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Value Stocks Walking a Fine Line
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
Via StockStory
News headline image
Biogen Announces Board Chair Transition
From Biogen Inc.
Via GlobeNewswire
News headline image
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds
Via StockStory
News headline image
Why Biogen Stock Surged Almost 9% Higher on Friday ↗
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Via MarketMinute
Topics Intellectual Property
News headline image
Biogen (BIIB) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 187.13
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 03/30/26 12:28 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 27.47B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 27B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story